Intravitreal and Intracameral DEX in NPDR

Affiliated Hospital of Nantong University

Status and phase: Invitation-only; Phase 3

Conditions: Non-Proliferative Diabetic Retinopathy

Treatments: Drug: Dexamethasone sodium phosphate

Study type: Interventional

Funder types: Other

Identifiers

NCT06951087

2019-K068

81974129, 82171038, 82101101 (Other Grant/Funding Number)

Details and patient eligibility

About

To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy

Full description

The study aims to analyze the impact of intravitreal and intracameral DEX in diabetic patients with NPDR who are undergoing phacoemulsification surgery. Specifically, the investigators will investigate its effects on postoperative macular central thickness, the development of DME, and the progression of DR.

Enrollment: 80 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

type 2 diabetic cataracts patients who were diagnosed with mild to moderate NPDR

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

80 participants in 3 patient groups

intravitreal DEX group

Experimental group

Description:

Patients received an intravitreal injection of 0.5 mg DEX during phacoemulsification in the intravitreal DEX group

Treatment:

Drug: Dexamethasone sodium phosphate

intracameral DEX group

Experimental group

Description:

Patients received an intracameral injection of 0.5 mg DEX during phacoemulsification in the intracameral DEX group

Treatment:

Drug: Dexamethasone sodium phosphate

the control group

No Intervention group

Description:

Patients received no injection during phacoemulsification in the control group